The breast Cancer Research FoundationPink Press · The breast Cancer Research Foundation® 2 winter...

A Message from Evelyn Lauder, Founder and ChairmanThis October, at our annual Symposium and Luncheon, we honored our “Super Heroes”; the 172 brilliant medical scientists from around the world who are changing the face of breast cancer. BCRF’s Super Heroes continue to gain momentum and are saving more lives each year. They are the best and the brightest, and it is a privilege to raise funds to support their enormous talent. Since 1993, BCRF has raised over $300 million to support research. I am so proud that we were able to award $33 million in grants to this year’s group of researchers. They represent 12 countries across the United States, Canada, Latin America, Europe, the Middle East and Australia.

Supporting BCRF means you are supporting the very best science in breast cancer in the world. BCRF continues to be one of the most efficient organizations—having received 4 stars from Charity Navigator for nine consecutive years, BCRF has outperformed 99% of more than 5,500 evaluated charities. Furthermore, the Foundation is consistently listed as an “A+” charity by The American Institute of Philanthropy.

People often praise me for my work at BCRF, but I truly know that all the praise should be directed to two groups – our wonderful staff at the Foundation and our Super Heroes: the men and women who dedicate their life’s work to finding an end to this disease or ensuring that we have ways to prevent breast cancer in the near future. When you talk to these scientists, you can’t help but feel their energy, their excitement, their enthusiasm, and their commitment to their research projects. They are our fuel. We are so close to living in a world where breast cancer is obsolete. With your continued support, our Super Heroes can make this a reality.

Wishing you a healthy and happy 2011.

Evelyn H. Lauder

BCRF 2010 Awards LuncheonHonoring our Super Heroes BCRF’s Annual Symposium and Awards Luncheon on October 27 was an exceptional occasion for a variety of reasons. Drawing more than 1,000 guests to The Waldorf=Astoria in New York City, the event raised over $2 million, and the Foundation awarded $33 million in grants to 172 researchers from around the world. It was especially poignant as the morning Symposium was dedi-cated to Josie Robertson, a beloved member of the BCRF Board of Directors who passed away in June. Evelyn Lauder described Mrs. Robertson as “an inspiration” who was fully committed to finding prevention and a cure for breast cancer since day one.

Surprising the audience with his presence, former President Bill Clinton welcomed the guests. “Every time I see a pink ribbon, it is very personal to me,” said Clinton, who spoke candidly about how breast cancer has impacted his life. As President, Clinton signed the Breast and Cervical Cancer Prevention and Treatment Act of 2000, which increased healthcare coverage for patients as a way to prevent families from being driven to bankruptcy because of medical costs. In his private role as the son of a mother who died from breast cancer, he articulated the all-too-familiar toll that the disease exacts on families. Sharing these intimate details, Clinton inspired everyone in the audience as to the reasons why supporting research must take center stage in the effort to prevent and cure breast cancer.

Myra Biblowit, Dr. Larry Norton, Evelyn Lauder and President Bill Clinton

continued on page 3

The breast Cancer Research Foundation®

Pink Press®

winter 2011

PHO

TO: R

ob R

ich

Pierce Brosnan and Judy Craymer

PHO

TO: J

ulie

Ska

rrat

t

PHO

TO: W

ire Im

age.

com

Foun

ded

in 1

993


2

win

ter

2011


UN

LESS

OTH

ERW

ISE

NO

TED

PH

OTO

S: J

ulie

Ska

rrat

t

Dr. Annette Stanton, Kay Krill, Dr. Carol Fabian, Evelyn Lauder and Dr. Dawn Hershman

Mike Tucci, Dr. Robert Schneider, Myra Biblowit; Drs. Silvia Formenti and Judy Garber; Evelyn Lauder and Todd Kahn

PHO

TO: R

ob R

ich

Dr. Joan Brugge and Anne Keating

Gail Hilson and Anne Sitrick

Perri Peltz, Danielle Ganek and Gigi Mortimer

Dr. Andrea Richardson, Jane and Neil Golub

Dr. Michael Press, Joanne Smith; Drs. Susan Horwitz, Hayley McDaid, Sofia Merajver and Adrian Harris

Tommy and Dee Hilfiger

PHO

TO: R

ob R

ich

PHO

TO: R

ob R

ich

PHO

TO: R

ob R

ich

Cynthia Lufkin and Muffie Potter Aston

3

Mrs. Lauder thanked everyone in the room for supporting our Super Heroes—the men and women who are working tirelessly to realize a cure for breast cancer in our lifetime. She then turned the program over to Dr. Larry Norton, who presented the 2010 Jill Rose Award to Dr. Angela Hartley Brodie.

Myra Biblowit set the stage for The Humanitarian Award, now named in memo-ry of Sandra Taub, daughter of devoted and steadfast supporters of the Foun-dation, Arlene and Joseph Taub. Actor Pierce Brosnan presented the 2010 Sandra Taub Humanitarian Award to Judy Craymer, the creator and producer of the global phenomenon Mamma Mia! Describing her as “one of those beau-tiful women who would change your life forever,” Brosnan recounted the ex-hilarating experience of working with Craymer – in spite of the fact that she had dressed him in tights. Craymer has been a staunch supporter of BCRF since 2001, following a serendipitous meeting with Evelyn Lauder on a trans-Atlantic flight. Inspired by their meeting, Craymer created the “Rock Chick Supremo” t-shirt, which is sold at all Mamma Mia! productions world-wide and has generated over $750,000 for BCRF. Impressing everyone in the audience with her sincerity in accepting the award, Craymer spoke directly to the BCRF grantees in the audience. “Life is about second chances, and that is what you give us. You are, after all, the rock stars of medical science.”

The Symposium and Awards Luncheon was made possible by underwriters Roz and Les Goldstein, Terry and Katie Wheatley of Tough Enough to Wear Pink, and Evelyn and Leonard Lauder. The Foundation also wishes to thank Co-Chairmen Roberta Amon, Anne Bass, Betsy Green, Joanne de Guardiola, Ronnie Heyman, Gail Hilson, Evelyn Lauder, Bonnie Englebardt Lautenberg, Cynthia Lufkin, Gigi Mortimer, Wendi Rose, and Arlene Taub.

Caryn Zucker and Tory Burch

Marshall Rose; Drs. Angela Hartley Brodie and Larry Norton; and Wendi Rose

Alex Robertson and Lizzie Tisch

Tommy and Dee Hilfiger

Dr. Kenneth Offit, Arlene Taub and Dr. Walter Willett

Dr. Michael Sporn, Tom Hipwell and Dr. Karen Liby

Jamee Gregory, Audrey Gruss, Anne Eisenhower Flöttl

PHO

TO: R

ob R

ich

PHO

TO: R

ob R

ich

PHO

TO: R

ob R

ich

Jenny Paulson and Joanne de Guardiola


4

win

ter

2011

Science The Complex Role of Hormones in Breast Cancer Development and Treatment: A View from the Experts


With an all-star panel consisting of BCRF’s Executive Board of Scientific Advisors and the 2010 Jill Rose Awardee, this year’s Symposium focused on The Many Faces of Hormones and Breast Cancer: Expert Views of Causation, Treatment and Prevention. The experts traced the early path of treatments for hormone-receptor-positive breast cancer, which is the most frequently occurring type of breast cancer, continuing on to new lines of scientific inquiry emphasizing individualized treatment and preventive care. This signature event brought together a breast cancer brain trust, including 140 of the 172 BCRF 2010-2011 grantees, to help an overflow audience of more than 500 guests get to the bottom of hormones – specifically estrogen – and breast cancer and what people can do to minimize risk and maximize treatment options. The scientists reminded the audience that the presence of estrogen in itself is not a risk factor for breast cancer, but that about 80% of breast cancers express the estrogen receptor, whose growth is fueled by estrogen.

At the panel’s center was Angela Hartley Brodie, PhD (Professor of Pharmacology and Experimental Therapeutics at the University of Maryland), recipient of the 2010 Jill Rose Award for Distinguished Scientific Achievement, in recognition of her seminal research in the development of aromatase inhibitors, drugs that stop the production of estrogen. Joining her on the panel from BCRF’s Executive Board of Scientific Advisors were BCRF’s Scientific Director, Larry Norton, MD, Director of Breast Cancer Programs at Memorial Sloan-Kettering Cancer Center; Nancy Davidson, MD, Director of the University of Pittsburgh Cancer Institute; Peter Greenwald, MD, Dr.PH, Director of the Division of Cancer Prevention and Control at the

National Cancer Institute; and Gabriel Hortobagyi, MD, Chairman of the Department of Breast Medical Oncology at the University of Texas, MD Anderson Cancer Center. Clifford Hudis, MD, BCRF Scientific Advisory Committee Chair and Chief of Breast Cancer Medicine at Memorial Sloan-Kettering Cancer Center, moderated the lively presentations.

When Dr. Brodie, this year’s honoree, began her research in the 1960s, very little was known about the relationship between estrogen and breast cancer. Scientists knew that there was a connection; Dr. Hortobagyi provided a historical example dating to the 1890s, when it was noted that surgical removal of ovaries of young breast cancer patients seemed to “cure” some of these women of the disease. Building on later work

that elucidated more precisely the link between estrogen and breast cancer, Dr. Brodie’s investigations spurred the development of aromatase inhibitors, used in post-menopausal women with breast cancer to stop the production of estrogen. Thanks to her work, there are three aromatase inhibitors on the market today and they are used to both treat breast cancer and prevent its return after surgery. They may even have a role in prevention, and research studies exploring this are underway. Dr. Brodie con-tinues to focus on resistance to the aromatase inhibitors, since as many as one-third of breast cancer patients do not respond to hormone therapy and a significant percentage of ER+ tumors eventually become less responsive.

Drs. Hortobagyi and Davidson each spoke about their work. The general guideline for treating women with ER+ breast cancer calls for tamoxifen when they are pre-menopausal and aromatase inhibitors after menopause. This is a good example of the specificity that researchers have been able to achieve; however, they have not yet reached the ultimate goal of truly individual-ized therapy which might include patient-specific treatment selection based not only on the characteristics of the tumor but also on other factors related to the patient as a whole. Dr. Davidson then spoke of the need to address challenges facing survivors who have to confront not only the possibility of their cancer’s recurrence and metastasis but also the long-term effects of therapeutics, such as chemo- or radiation therapy. Hormone therapies are typically associated with fewer side effects but studies continue to find even safer ways to use them.

Dr. Greenwald shared with the audience his expertise on cancer prevention, telling them that “breast cancer prevention starts with your life habits, including diet and exercise.” He explained that data from the first generation of prevention studies showed that lifestyle changes, such as weight loss and reduced consumption of alcohol, lower the risk of developing cancer. With respect to weight, studies have shown that obesity increases estrogen and inflammation levels, the elevation of which exposes women to greater risk of breast cancer. As far as environmental factors that have been attributed to the incidence of breast cancer, Dr. Greenwald pointed out that it is very difficult to measure the level of toxins in a population, so direct cause and effect has not yet been demonstrated.

Drs. Clifford Hudis, Angela Hartley Brodie, Gabriel Hortobagyi, Nancy Davidson, Peter Greenwald and Larry Norton

PHO

TO: R

ob R

ich

5

The Symposium concluded with a lively exchange among the audience, panelists, and many of the BCRF grantees. Part of the discussion clarified the distinction between hormonal treatment for breast cancer, which works by blocking or lowering estrogen levels in the body, and hormone replacement therapy (HRT) after menopause, use of which has fallen off since clinical trials demonstrated that the estrogen in HRT can increase the risk of breast cancer development. HRT did not provide many of the benefits people thought it would. “Cancer is complex but has an Achilles’ heel, and it is our job to find its weaknesses and exploit them,” summarized Dr. Norton. “Are there easy answers? No. Are there hints? Absolutely!”

Research Retreat for GranteesThe enthusiasm at the Symposium matched the energy at the scientific retreat for BCRF researchers that took place the day before. The annual retreat, sponsored by Muriel Siebert, followed a “think tank” format, and researchers participated in one of six sessions: Biomarkers; Cancer Stem Cells and Cancer/Stroma Interactions; Therapeutic Targets/Targeted Therapeutics; Cancer Susceptibility Genes; Molecular Classification, Prognostication and Prediction; and Prevention and Survivorship. In each group, investigators brainstormed the most important “next steps” in breast cancer research, and then the entire group met to hear summaries from group moderators. As a take-away to be shared among the participants, Dr. Norton requested that each researcher submit a sentence describing her or his “Zen wisdom” about the most important research advance discussed, and another describing the greatest impediment to progress. Responses to date have centered on a few main themes and concerns, including the as-yet unrealized goal of therapy that is truly personalized, the need to better unify research on the discovery of new biomarkers for breast cancer, and more recognition of the very broad genetic diversity within individual breast cancers. This event embodies BCRF’s commitment to encouraging dialogue and fostering collaboration among breast cancer researchers from all corners of the globe.

Grantees in the News

In June 2010, Kathryn B. Horwitz, PhD, Distinguished Professor at the University of Colorado School of Medicine, received the Fred Conrad Koch Award, the highest honor bestowed by The Endocrine Society, in recognition of exceptional contribu-tions to the field. Dr. Horwitz has also been chosen to receive the 10th Rosalind E. Franklin Award for Women in Science from the National Cancer Institute to be presented in January 2011.

In September, President Cristina Fernandez de Kirchner of Argentina formally launched the National Cancer Institute of Argentina and appointed Eduardo L. Cazap, MD, PhD, Deputy Director of the Institute. Dr. Cazap is President and Founder of Latin American & Caribbean Society of Medical Oncology (SLACOM) and President of International Union Against Cancer. Silvia C. Formenti, MD was honored at the NYU Cancer Institute Gala on October 5, for her contributions to cancer care and research. Dr. Formenti is the Sandra and Edward H. Meyer Professor of Radiation Oncology, the Chair of the Department of Radiation Oncology, and co-leader of the Breast Cancer Research Program at NYU Langone Medical Center.

Two BCRF grantees were elected as new members of the Institute of Medicine (IOM) in October. Charis Eng, MD, PhD, Professor of Genetics and Chair and founding Director of the Genomic Medicine Institute of the Cleveland Clinic, and Titia de Lange, PhD, the Leon Hess Professor at The Rockefeller University, joined 63 fellow scientists and five foreign associates as IOM’s Class of 2010. As the health arm of the National Academy of Sciences, the IOM functions as an authoritative body advising both decision makers and the public, with the underlying mission of improving human health.

In November, Mary-Claire King, PhD received the Pearl Meister Greengard Prize from The Rockefeller University for her research which has advanced the science of genetics and improved medicine for the benefit of humankind. Dr. King also was awarded the 2010 Double Helix Medal from Cold Spring Harbor Laboratory for her major contributions to understand-ing the genetics of breast cancer. Sharing the same honor, Evelyn Lauder was recognized for her efforts in raising aware ness and support for clinical and translational research on breast cancer at medical institutions across the globe.

On November 18, José Baselga, MD, PhD was awarded the 2010 Queen Sofía Spanish Institute’s Gold Medal, representing Spain’s leadership in the area of cancer research. Dr. Baselga, Associate Director of the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School, was previously the Director of the Vall d’Hebron Institute of Oncology in Barcelona.


6

win

ter

2011

Q & A with Dr. Carol Fabian

Q: Tell us about yourself as a scientist and how you became interested in breast cancer research. Did you ever seriously consider another kind of career than that of the sciences?My interest in science dates back to my early college days. I was first attracted to psychology, then microbiology, and finally medicine. I never did consider another type of career other than the sciences.

I became interested in breast cancer research during fellowship training in oncology. Although I was interested in a variety of different types of cancer, I was particularly drawn to breast cancer because it seemed like so many young women at the time were being affected by the disease.

Q: What factors have motivated you to continue studying this field?My interest in risk assessment and prevention research came about 15 years after I started treating cancer patients. When I completed training in the 70s there was tremendous excitement in oncology. We thought almost every woman with early breast cancer could be cured with the right combination of adjuvant treatment. That is still the basic premise of treatment research and we have made tremendous strides in the past 35 years. However, after a decade and a half of oncology practice, it became very painfully obvious to me that many women who had early breast cancer were not go-ing to be cured despite doing everything “right.” That is, they got their yearly mammograms, the cancer seemed to have been detected early, and they received aggressive adjuvant therapy; yet, many still relapsed and died. In addition, many women who did appear to be cured had lingering side effects which reduced their quality of life. Prevention of breast cancer by blocking or reversing precancerous changes with medication rather than waiting for it to happen seemed to make sense.

The early days (circa 1990) of working in risk assessment and prevention were a little tough. We needed tools to predict who was at highest short-term risk and who was likely to respond to therapy. My team and I refined a fine-needle aspira-tion (FNA) technique so that we were able to get representative breast tissue, kind of like a “pap smear” for the breast tissue, to test for signs of precancerous change and, thereby enabling doctors to more accurately assess a person’s short-term risk of developing breast cancer and target appropriate women for prevention treatment. While this made infinite sense to us, it did not to most others. Conventional wisdom was that you did not put a needle into a woman’s breast unless you had a lump or other abnormality to aim at.

We were, however, eventually able to show that for women who had a family history of breast cancer or who had a prior precancerous biopsy, random sampling of her breast tissue by FNA could more accurately predict short-term risk than by using risk models alone. Once we were able to demonstrate that we could better predict which women were at high short-term risk of developing breast cancer, the challenge became to apply clinical prevention interventions. Concerns over possible side effects keep many women from using standard prevention options such as tamoxifen, or raloxi fene, or even prophylactic surgery. Consequently, we began early-phase testing of interventions with fewer effects using the FNA technique to sample tissue before and after the intervention. One of our goals was to make the aspirations as comfortable as possible so that the patients would come back and get them again.

Q: Briefly describe your BCRF-funded research project. What are some laboratory and/or clinical experiences that inspired your work? What are your primary goals for this research?My first BCRF project, which is still ongoing, is developing new tissue-based biomarkers for women who are at increased risk of breast cancer but whose tissue samples obtained by FNA did not have a high growth (or proliferation) rate even though it might have some atypical looking cells. These women are primarily post-menopausal, overweight women who are not on hormone replacement therapy. Although these women have very low proliferation rate in their benign tissue, they can still develop cancer over time. Part of the reason is that inflammatory cytokines and adipokines may promote survival and more aggressive behavior of atypical cells.

In conjunction with Dr. Stephen Hursting, another BCRF researcher at the University of Texas, we started looking at inflammatory markers in breast tissue and blood. We found that we could measure the inflammation markers reliably in the breast tissue. We are currently trying to make sure that in the absence of an intervention (i.e., drugs or weight loss, etc.) that these markers are still consistently expressed over time.

Professor of Internal MedicineKansas Masonic Cancer Research Chair Director, Breast Cancer Prevention and Survivorship Centers University of Kansas Medical Center Kansas City, Kansas

7

Building on the first two years of our BCRF research, we have developed new pilot trials (one of which is funded by BCRF) using high-dose omega 3 fatty acids and have proposed trials using energy balance interventions.

Q: How close are we to preventing and curing all forms of breast cancer?At the time I completed my training in the mid-1970’s, 40% or more of the women who developed breast cancer were dying from it. Now fewer than 20% of women, who were undergoing regular screening at the time their breast cancer was discovered, will ultimately die of their disease. Although that figure is still too high, the change over 35 years is amazing.

For prevention, we have identified drugs that will reduce by half the 5-to-10 year risk of developing breast cancer. The problem is few risk-eligible women will take them. So, I think we have to look at multiple prevention strategies, emphasizing interventions likely to be attractive to women at different stages of their life. The emphasis should be on things that women can do themselves which do not require extensive medical monitoring. These interventions ideally should make them look better and feel better (like diet and exercise). We also need to give a map and a toolbox such that they can accomplish their goals. I see prevention going in that direction.

Q: In your opinion, how has BCRF impacted breast cancer research?BCRF has impacted breast cancer research in at least two very important ways. One is that the organization stimulates cross-collaboration by bringing together established breast cancer researchers from various fields. The collaboration between Dr. Hursting’s and my group is an example. BCRF is also unique in that it supplies funds needed to develop the clinical and translational tools and the preliminary data needed to perform research. Having the tools and pilot data accelerates the pace of breast cancer research. Read the entire Q&A on www.bcrfcure.org.

BCRF Hosts Conference in Israel on Inherited Breast and Ovarian CancerOn November 18 and 19, BCRF co-hosted its first international scientific meeting, a symposium in Tel Aviv, on Clinical Dilemmas in Management of Breast and Ovarian Cancer in BRCA Carriers. BCRF’s participation was made possible by a contribution from Advisory Board member Roslyn Goldstein and her husband, Les. Chaired by BCRF Scientific Director, Larry Norton, MD, the conference was attended by more than 150 medical oncologists, surgeons, radiation oncologists and other medical professionals from the Mideast, Europe, Australia and North America; session chairs included BCRF grantees Drs. Judy Garber (Boston) and Fatima Cardoso (Lisbon), and presenters included Drs. Ephrat Levy-Lahad (Jerusalem) and Moein Kanaan (Palestinian Authority). In her keynote, BCRF grantee Mary-Claire King, PhD (Seattle) credited BCRF support for studies conducted jointly in the US, Israel and the Palestinian Authority, as responsible for the creation of a data pool to sequence all critical genes involved in breast cancer development and to identify mutations known to be deleterious. She cited the complexity of the challenge to unravel the genetic basis of the disease: while there are three known mutations of Ashkenazi origin, there are 1,000 known mutations on BRCA1 and an equal number on BRCA2. The content of the presentations reflected the collaborative spirit of BCRF research. Drs. Levy-Lahad and Kanaan described their joint efforts with Dr. King to determine the genetic basis of inherited predisposition to breast cancer in the Palestinian Arab population, and to create the infrastructure for providing cancer genetics services to these women. Dr. Garber provided an overview of the search for new treatments that can be used as chemopreventive agents for individuals at high risk. She cited work by BCRF grantees at Dartmouth, Drs. Michael Sporn and Karen Liby, who have shown in the laboratory that PARP inhibitors have potential for use in prevention. In closing the meeting, Dr. Norton said that breast cancer research is “a model for collaborative effort; there are relatively few areas where there is such integration between laboratory science and clinical practice.” Highlights from the conference are on www.bcrfcure.org

2011 Unsung Hero NeededOn April 14, the Unsung Hero Award, established by Roz and Les Goldstein, will be presented at the

NYC Hot Pink Party to a special individual who has been a source of support, hope, humor, strength and comfort to a woman facing breast cancer.

Send nominations to Myra Biblowit by February 1: [email protected] or 646-497-2601

Dr. Judy Garber

Drs. Fatima Cardoso, Mary-Claire King, Larry Norton; Peg Mastrianni; Drs. Suheir Lolas-Hamame and Ephrat Levy-Lahad


8

win

ter

2011

Albert Einstein College of MedicineNew York, NY

Rachel Hazan, PhDThe First Step Award, made possible by QVC & Fashion Footwear Charitable Foundation

Susan B. Horwitz, PhDMade possible by Delta Air Lines, Inc.

Hayley McDaid, PhDMade possible by Delta Air Lines, Inc.

Thomas E. Rohan, MD, PhD

Arizona State UniversityThe Biodesign Institute Tempe, AZ

Joshua LaBaer, MD, PhD

Baylor College of MedicineHouston, TX

C. Kent Osborne, MD

Rachel Schiff, PhD

Beth Israel Deaconess Medical Center/Harvard Medical SchoolBoston, MA

Lewis C. Cantley, PhD

Stuart J. Schnitt, MDThe Housewares Charity Foundation Award

Nadine M. Tung, MDThe Housewares Charity Foundation Award

Bethlehem UniversityBethlehem, Palestinian Authority

Moein Kanaan, PhD

Brigham & Women’s Hospital/Harvard Medical SchoolBoston, MA

Ross Berkowitz, MD

Monica Bertagnolli, MDOn behalf of Cancer and Leukemia Group B

Cancer Institute of New Jersey/University of Medicine & Dentistry of New JerseyNew Brunswick, NJ

Bruce G. Haffty, MDThe Play for P.I.N.K Award

Kim Hirshfield, MD, PhD

Arnold J. Levine, PhDThe Institute for Advanced Study

CHS National Cancer Control CenterCarmel Medical CenterHaifa, Israel

Gad Rennert, MD, PhD

Champalimaud Cancer CenterLisbon, Portugal

Fatima Cardoso, MDBreast International Group/NABCG

Children’s Hospital/Harvard Medical SchoolBoston, MA

Marsha Moses, PhDMade possible by Clinique

Zoltan Szallasi, MD

Cleveland ClinicCleveland, OH

Charis Eng, MD, PhD, FACP

Coalition of Cancer Cooperative GroupsEastern Cooperative Oncology GroupPhiladelphia, PA

Robert L. Comis, MDMade possible by Pfizer, Inc.

Cold Spring Harbor LaboratoryCold Spring, NY

Michael H. Wigler, PhDThe Play for P.I.N.K. Award

Columbia University MailmanSchool of Public HealthNew York, NY

Regina M. Santella, PhD Made possible by Aveda

Mary Beth Terry, PhDMade possible by Aveda

Columbia University Medical CenterNew York, NY

Dawn Hershman, MD, MSMade possible by Ann Taylor Stores Corporation

Dana-Farber Cancer Institute/Harvard Medical SchoolBoston, MA

Judy E. Garber, MD, MPHThe Coach Award

J. Dirk Iglehart, MDMade possible by Price Chopper

William G. Kaelin, Jr., MD

Nancy U. Lin, MDThe Play for P.I.N.K. Award

David M. Livingston, MD

Ursula A. Matulonis, MD

Kornelia Polyak, MD, PhD

Andrea L. Richardson, MD, PhDMade possible by Price Chopper

Zhigang Charles Wang, MD, PhD

Dartmouth Medical SchoolHanover, NH

Karen T. Liby, PhDMade possible by Nestlé Pure Life

Michael B. Sporn, MDMade possible by Nestlé Pure Life

Duke UniversityDurham, NC

John A. Olson, Jr., MD, PhD On behalf of ACOSOG

David Ota, MDOn behalf of ASOCOG

Emory University on behalf of NABCG/Breast International GroupAtlanta, GA

William C. Wood, MDMade possible by Genentech

Fred Hutchinson Cancer Research CenterSeattle, WA

Peggy L. Porter, MDOn behalf of Southwest Oncology GroupThe Play for P.I.N.K. Award

Harvard Medical SchoolBoston, MA

Joan S. Brugge, PhD Made possible by Bloomingdale’s

Harvard School of Public HealthBoston, MA

Walter C. Willett, MD, Dr.PHMade possible by Wilson Sporting Goods

Hospital of PratoIstituto Toscano TumoriPrato, Italy

Angelo Di Leo, MD, PhD

Hunter CollegeCity University of New YorkNew York, NY

Jill Bargonetti, PhDMade possible by Estée Lauder

Indiana University School of MedicineIndianapolis, IN

Susan E. Clare, MD, PhDMade Possible by ULTA

Kathy D. Miller, MDMade possible by Ann Taylor Stores Corporation

George W. Sledge, MD

Anna Maria Storniolo, MDMade possible by ULTA

INSERM, Centre René HugueninParis, France

Rosette Lidereau, PhD

Institut Jules BordetBrussels, Belgium

Martine J. Piccart-Gebhart, MD, PhDBreast International Group/TRANSBIGMade possible by Roche

Christos Sotiriou, MD, PhD

Institute of Cancer Research UKLondon, UK

Alan Ashworth, BSc, PhD, FRSMade possible by Hard Rock International

International Breast Cancer Research FoundationColumbus, OH

Richard R. Love, MD, MSOhio State University

Johns Hopkins Bloomberg School of Public HealthBaltimore, MD

Kala Visvanathan, MBBS, FRACP, MHS

Johns Hopkins University School of MedicineBaltimore, MD

Ben Ho Park, MD, PhD

Vered Stearns, MDMade possible by The Estée Lauder East Coast Field

Antonio C. Wolff, MDTranslational Breast Cancer Research Consortium (TBCRC)

Richard C. Zellars, MD

Mayo Clinic: Rochester, MN and Jacksonville, FL

Debra L. Barton, RN, PhD, AOCN

Fergus J. Couch, PhDOn behalf of CIMBA

James N. Ingle, MDThe Play for P.I.N.K. Award

Charles L. Loprinzi, MD

Edith A. Perez, MDThe Play for P.I.N.K. Award

Memorial Sloan-Kettering Cancer CenterNew York, NY

Robert Benezra, PhDThe Play for P.I.N.K. Award

Monica N. Fornier, MD

Teresa Gilewski, MD

Alan N. Houghton, MD The Peter Jay Sharp Foundation Award

Hedvig Hricak, MD, PhDMade possible by Macy’s

Clifford Hudis, MD

Johanna A. Joyce, PhD

Philip O. Livingston, MD

Shanu Modi, MDASCO Cancer Foundation

Larry Norton, MDThe Peter Jay Sharp Foundation AwardThe First Step Award, made possible by QVC & Fashion Footwear Charitable Foundation

Kenneth Offit, MD, MPHThe Sandra Taub Memorial Award

Mark E. Robson, MDThe Sandra Taub Memorial Award

Neal Rosen, MD, PhDThe Joseph and Arlene Taub Foundation Award

Charles L. Sawyers, MD

The Methodist Hospital Research InstituteHouston, TX

Jenny Chang, MD

Mount Sinai HospitalUniversity of TorontoToronto, Ontario, Canada

Pamela J. Goodwin, MD, MSc, FRCPC

Mount Sinai School of MedicineNew York, NY

Stuart A. Aaronson, MDThe Housewares Charity Foundation Award

National Surgical Adjuvant Breast and Bowel Project (NSABP)Pittsburgh, PA

Soonmyung Paik, MD

Northwestern UniversityFeinberg School of MedicineChicago, IL

Charles Clevenger, MD, PhDAmerican Association for Cancer Research

Vincent L. Cryns, MDThe Housewares Charity Foundation Award

William J. Gradishar, MD, FACPThe Housewares Charity Foundation Award

NYU School of MedicineNew York, NY

Silvia Formenti, MD The Coach Award

2010 - 2011 Grantees

PHO

TO: R

ob R

ich

9

Robert J. Schneider, PhDThe Coach Award

Ohio State University Columbus, OH

Electra D. Paskett, PhDThe Play for P.I.N.K. Award

Queen’s UniversityKingston, Ontario, Canada

Lois Shepherd, MDCM, FRCP(C)On behalf of NCIC Clinical Trials Group

The Rockefeller UniversityNew York, NY

Titia de Lange, PhDMade possible by Bloomingdale’s

Paul M. Nurse, PhD

Roswell Park Cancer InstituteBuffalo, NY

Christine B. Ambrosone, PhDMade possible by Prime Retail

Royal Marsden Hospital and Institute of Cancer ResearchLondon, UK

Mitch Dowsett, PhD, BScThe Elizabeth Hurley Award

Ian E. Smith, MD, FRCP, FRCPEThe Elizabeth Hurley Award

Salk Institute for Biological StudiesLa Jolla, CA

Geoffrey M. Wahl, PhD

Sarah Lawrence CollegeBronxville, NY

Joan H. Marks, MSNew York Breast Cancer Study

Shaare Zedek Medical CenterJerusalem, Israel

Ephrat Levy-Lahad, MD

Sir Mortimer B. Davis – Jewish General Hospital/McGill UniversityMontreal, Quebec, Canada

Wilson H. Miller, MD, PhDAmerican Association for Cancer Research

Latin American and Caribbean Society of Medical Oncology (SLACOM)Buenos Aires, Argentina

Eduardo Cazap, MD

Stanford University School of MedicineStanford, CA

Michael F. Clarke, MD

James M. Ford, MDThe Pink Promises Award in memory of Patricia L. Hansen

Shaveta Vinayak, MDASCO Cancer Foundation

Tel Aviv UniversitySackler School of MedicineTel Aviv, Israel

Ilan Tsarfaty, PhD

Thomas Jefferson UniversityKimmel Cancer CenterPhiladelphia, PA

Andrew A. Quong, PhD

Tufts University School of MedicineBoston, MA

Charlotte Kuperwasser, PhDMade possible by Saks Fifth Avenue

University of CaliforniaIrvine, CA

Eva Y.-H. P. Lee, PhD

University of CaliforniaJonsson Comprehensive Cancer CenterLos Angeles, CA

Patricia A. Ganz, MDMade possible by Estée Lauder

Mary Sehl, MD, PHDASCO Cancer Foundation

Annette L. Stanton, PhDMade possible by Ann Taylor Stores Corporation

University of CaliforniaRebecca and John Moores Cancer CenterSan Diego, CA

Barbara A. Parker, MDMade possible by Macy’s

University of CaliforniaSan Francisco, CA

Laura J. Esserman, MD, MBA

Shelley Hwang, MD, MPHOn behalf of Cancer and Leukemia Group B

Hope S. Rugo, MDThe Housewares Charity Foundation Award

Laura J. van ‘t Veer, PhD

University of CambridgeCambridge, UK

Sir Bruce A. J. Ponder, PhD, FRCP, FRSCancer Research UK

University of Chicago Medical CenterChicago, IL

Funmi I. Olopade, MB, BS, FACPMade possible by Macy’s

Monika Burness, MDASCO Cancer FoundationThe Hirschhorn Award

University of Colorado Health Sciences CenterDenver, CO

Kathryn B. Horwitz, PhD

University of EdinburghEdinburgh, Scotland

John Bartlett, PhDBreast International Group/NABCG

University of Illinois at Urbana-ChampaignUrbana, IL

Benita S. Katzenellenbogen, PhDThe Play for P.I.N.K. Award

University of Kansas Medical CenterKansas City, KS

Carol J. Fabian, MDMade possible by Ann Taylor Stores Corporation

University of Miami Miami, FL

Tan A. Ince, MD, PhDMiller School of MedicineThe Play for P.I.N.K. Award

Marc E. Lippman, MDMiller School of MedicineThe Play for P.I.N.K. Award

Joyce Slingerland, MD, PhD, FRCP(C)Braman Family Breast Cancer Institute The Housewares Charity Foundation Award

University of MichiganAnn Arbor, MI

Daniel F. Hayes, MDNABCG/Breast International GroupMade possible by Eisai Oncology

Sofia D. Merajver, MD, PhDMade possible by Delta Air Lines, Inc.

Lori J. Pierce, MDMade possible by ULTA

James M. Rae, PhD

Shaomeng Wang, PhD

Stephen J. Weiss, MD

Max S. Wicha, MD

University of Newcastle, on behalf of Australian New Zealand Breast Cancer Trials Group, Australia

John Forbes, MB, BS

University of North CarolinaLineberger Comprehensive Cancer CenterChapel Hill, NC

Lisa A. Carey, MDMade possible by Saks Fifth Avenue

H. Shelton Earp, MDMade possible by The Estée Lauder Field

Hyman B. Muss, MD

Charles M. Perou, PhD Made possible by Susan Hertog

University of Oxford Oxford, UK

Adrian Harris, MD, D.PhilCancer Research UKMade possible by Delta Air Lines, Inc

University of PennsylvaniaAbramson Cancer CenterPhiladelphia, PA

Lewis A. Chodosh, MD, PhD

Susan M. Domchek, MDMade possible by Hard Rock International

Mark I. Greene, MD, PhD, FRCPThe Play for P.I.N.K. Award

Katherine L. Nathanson, MD

Robert H. Vonderheide, MD, D.PhilMade possible by Hard Rock International

University of Pittsburgh Cancer CenterPittsburgh, PA

Nancy E. Davidson, MDNABCG/Breast International GroupMade possible by Genentech

Shannon Puhalla, MDASCO Cancer Foundation

University of Southern CaliforniaNorris Comprehensive Cancer Center Los Angeles, CA

Michael F. Press, MD, PhDMade possible by Delta Air Lines, Inc.

University of SydneySydney, Australia

Janette Vardy, MD, FRACP, PhDASCO Cancer Foundation

University of TexasAustin, TX

Stephen D. Hursting, PhD, MPH

University of TexasMD Anderson Cancer CenterHouston, TX

Isabel Bedrosian, MD

Powel H. Brown, MD, PhD

Francisco J. Esteva, MD, PhD

Zhen Fan, MD

Sharon Giordano, MD, MPHNABCG/Breast International Group

Ana Maria Gonzalez-Angulo, MD, MScOn behalf of Southwest Oncology Group

Gabriel N. Hortobagyi, MD, FACP

Mien-Chie Hung, PhD

Kelly K. Hunt, MD, FACSOn behalf of ACOSOG

John Mendelsohn, MD

Gordon B. Mills, MD, PhD

Lajos Pusztai, MD, D.Phil

W. Fraser Symmans, MD

University of WashingtonSeattle, WA

Julie R. Gralow, MDOn behalf of Southwest Oncology GroupThe Play for P.I.N.K. Award

Mary-Claire King, PhD New York Breast Cancer Study

Vall d’Hebron Institute of OncologyBarcelona, Spain

Joaquín Arribas, PhD

José Baselga, MDMassachusetts General HospitalThe Housewares Charity Foundation Award

Van Andel Research InstituteGrand Rapids, MI

George F. Vande Woude, PhD

Vanderbilt University School of MedicineNashville, TN

Carlos L. Arteaga, MDThe von Mandl Family Award

Washington University School of MedicineSt. Louis, MO

D. Craig Allred, MD

Graham A. Colditz, MD, Dr.PH

Matthew J. Ellis, MD, PhDOn behalf of ACOSOG

Weill Medical College of Cornell UniversityNew York, NY

Andrew J. Dannenberg, MD

Whitehead Institute for Biomedical ResearchCambridge, MA

Robert A. Weinberg, PhD

Yale University School of MedicineNew Haven, CT

Lyndsay N. Harris, MD


10

win

ter

2011

Elizabeth Hurley Researchers Announced at Winfield HouseOn October 18, at a reception hosted by U.S. Ambassador Louis Susman and Mrs. Marjorie Susman at Winfield House in London, The Breast Cancer Research Foundation honored Elizabeth Hurley for spreading the message globally about the urgency of funding research and also honored five BCRF-funded United Kingdom-based researchers for their stellar work. The first annual Elizabeth Hurley Researcher Award was bestowed upon the team of Drs. Ian Smith and Mitch Dowsett (Royal Marsden Hospital/Institute of Cancer Research, London). Also in attendance were Dr. Alan Ashworth (Institute of Cancer Research), Dr. Adrian Harris (Oxford University), and Sir Bruce Ponder (Cambridge University).

A dinner at Bar Boulud London, underwritten by LEVIEV, immediately followed to celebrate the great science being conducted in the UK with BCRF’s support. To date, BCRF has invested nearly $4 million in breast cancer research based in the UK, with nearly $1 million in 2010 alone.Photos (top to bottom): Dr. Mitch Dowsett, Elizabeth Hurley and Dr. Ian Smith; Elizabeth Hurley, David and Lisa Klein; Ambassador Louis Susman and Marjorie Susman

Hudson BCRF Golf ClassicThe inaugural Hudson BCRF Golf Classic at Liberty National in NJ on July 12, raised over $525,000. After a sunny day of golf, guests enjoyed a cocktail reception with a special viewing of Michael Fux’s private luxury car collection. Celebrity golfers included sports stars Dan Marino, Jason Taylor, and Alonzo Mourning. Special thanks to Co-Chairs William Lauder and Paul Fireman, along with the support of major sponsors Hudson, The Paul & Phyllis Fireman Charitable Foundation, William Lauder, American Express, Cartier, Rolls-Royce, and The Michael Fux Foundation.Photos (top to bottom): Dan Marino, Peter Kim, William Lauder, Paul Fireman and Michael Fux; Ida Rothbaum, Mark Shirvan, Scott Tesser and Joe Rosen

Westchester LuncheonFor the fifth year, BCRF Advisory Board member Shelly Kivell, and Co-Chairs Ellen Brown, Debra Ezratty, Sheryl Kaye and Kim Meyers, organized a Luncheon at Fenway Golf Club in Scarsdale, NY, raising more than $180,000 from over 200 guests.

BCRF Scientific Advisory Committee Chairman, Dr. Clifford Hudis, gave an overview of Breast Cancer: Progress and Promise that began with a historical perspective of biomedical research funding in the U.S. He made the point that the Foundation’s grants program is akin to the MacArthur Foundation’s “genius awards” in that BCRF’s Scientific Advisors seek out the most talented

investigators with creative ideas and they are given the freedom to pursue their ideas with minimum bureaucracy. In Dr. Hudis’s words, “there is no other grants program like it” and BCRF-funded scientists have played a role in every important advance in breast cancer research since 1993.

He told the audience that, while more targeted therapies for breast cancer and more precise measures of risk reduction are needed, it is important to remember that there has been steady progress. Breast cancer mortality rates have been falling since 1990, in a longer-living population that is more prone to being overweight. Many large-scale studies are underway to identify better and more effective treatments and improve quality of life for breast cancer survivors.

Front row L-R: Debra Ezratty, Kim Meyers, Dr. Clifford Hudis, Evelyn Lauder and Myra BiblowitBack row L-R: Sheryl Kaye, Shelly Kivell, Ellen Brown

PHO

TOS:

Ric

hard

Lew

is

PHO

TOS:

Mic

hael

Bla

ncha

rd

11

Letter from our President

This year, I am proud to report that BCRF is awarding grants totaling $33 million to 172 researchers from 12 countries around the world. Those are big dollars and you may ask, what is that investment yielding in 2011? What are the most promising opportunities where our funding can make a material difference in the lives of women, both in surviving the disease and preventing it altogether? BCRF’s grantmaking is organized around two main themes: Finding the Cause—whether that means inherited risk factors, environmental factors, or even when good cells go bad; and Finding the Cure—endeavors such as the development of

vaccines; the ability to assess risk for breast cancer development, and also for recurrence; the creation of new targeted therapies; and empowering breast cancer survivors to lead the healthiest possible lives on their road to complete recovery. Over the past 16-plus years, BCRF’s grantees have been responsible for some of the most important breakthroughs to date in breast cancer research. They are truly the “who’s who” of breast cancer research. Whenever a new advance is reported, you will see a BCRF grantee’s name. Your generous support is what has been driving and leveraging incredible scientific progress and hope. Thank you for enabling BCRF’s army of brilliant minds to take on the resolution of breast cancer through multi-faceted approaches. We hope that we can continue to count on your support as we push forward towards our goal of eradicating breast cancer in our lifetime.

Sincerely,

Myra J. Biblowit

PHO

TO: J

ulie

Ska

rrat

tPink Promises

On October 1, BCRF kicked off breast can-cer awareness month with the inaugural Pink Promises benefit at Crest Hollow Country Club in Woodbury, NY. BCRF Advisory Board member Stephanie Ginsberg served as event Co-Chair along with her husband Ian, President of C.O. Bigelow. Over 950 guests attended this sold-out event, which featured unique auction items, raffle prizes, and fabulous cocktails donated by Mike’s Hard Lemonade.

The ballroom was adorned with sequin overlays and diamond encrusted centerpiec-es, in keeping with the evening’s Denim and Diamonds theme. The Mistress of Ceremonies, LXTV anchor Sara Gore, introduced Stephanie. Stephanie spoke lovingly about her sister Betsy, who has been battling triple negative breast cancer for the past five years and is the motivation behind the Ginsbergs’ personal commitment to Pink Promises—“to raise significant funds…so we may all see a cure in our lifetime.” Then, Honorary Chairman Evelyn Lauder expressed her

enthusiasm and utmost gratitude for the remarkable turnout from the Long Island community. BCRF grantee and keynote speaker Dr. Robert Benezra of Memorial-Sloan Kettering Cancer Center, shared a few words regarding his research on breast tumor growth, angiogenesis, and metastasis that is made possible through BCRF funding. The excitement swelled when popular appraiser and host of PBS’s History Detectives, Elyse Luray, conducted the live auction, and pop singer Matisse ended the night on a high note with her live performance.

Pink Promises was a huge success, raising over $850,000, demonstrating Long Island’s strong commitment to finding a cure. The event was made possible by premier underwriters C.O. Bigelow, The Buller Family Foundation and Marjam Supply Company, along with lead underwriters BNY Mellon and The Estée Lauder Companies Inc. Special thanks to sponsors Americana Manhasset, Duffy & Duffy, Sharon and Rich Greenstein, the Jaffee Family, Perfumania, and Tanger Outlet Centers. Sincere thanks to the wonderful Host Committee for their hours of dedication.

Photos (top to bottom): Rita & Frank Castagna and Evelyn Lauder; Wendy, Alec, Ian, Stephanie and Reed Ginsberg; Sarah & Mark Buller and Cherie & James Buller

PHO

TOS:

Rob

Ric

h


12

win

ter

2011

2010: Play for P.I.N.K. Reaches New Heights On October 27, Play for P.I.N.K.’s (PFP) Board proudly presented a record-breaking $3.25 million check to Evelyn Lauder and The Breast Cancer Research Foundation, bringing its cumulative contribution to $22 million! Representatives from Bloomberg and The Estée Lauder Companies joined the PFP board for this special moment. Honored guests included many of the PFP-funded researchers; Dr. Larry Norton, BCRF Scientific Director and Chairman of the BCRF Executive Board of Scientific Advisors; and Dr. Clifford Hudis, Chairman of the BCRF Scientific Advisory Committee.

This amazing donation was made possible by an unparalleled number of participants with an increase in both clubs and events. More than 220 clubs in over twenty-four states got behind PFP this year.

This phenomenal growth would not be possible without our dedicated board, chairwomen, participants, and of course our generous sponsors. Bloomberg, our title sponsor, underwrites all of the expenses of PFP, enabling 100% of the proceeds to be donated to BCRF. The Estée Lauder Companies and Wilson Sporting Goods support PFP through their contribution of gifts and merchandise.

We thank you for your tremendous P.I.N.K. support and look forward to another successful year in 2011!

Think P.I.N.K. Be in the know. Visit www.playforpink.org or call me at 646-497-2605 to find out about ongoing happenings, how to get involved, or to make a donation.

Sincerely,

Stephanie HamburgerDirector, Play for P.I.N.K.

Delta “Taking Flight for the Fight”Led by Delta CEO Richard Anderson on September 30, 100 Delta employees who are breast cancer survivors, flew in the new pink Boeing 767 from Atlanta to Detroit to Minneapolis to inaugurate Delta’s annual breast cancer program to support BCRF. In addition to donating proceeds from onboard “pink” sales, Delta had a virtual lemonade stand on Facebook and donated SkyMiles to BCRF when customers downloaded the Delta iPhone

application. In its sixth year, Delta and its dedicated employees have helped raise over $2.5 million cumulatively for BCRF and are currently supporting four research projects around the world.

13

Ann Taylor and LOFT Continue to Raise the Philanthropic BarAnn Taylor Stores Corporation, under the leadership of CEO Kay Krill, raised an unprec-edented $2.6 million for BCRF through their ANN Cares® Card and LOFT Cares® Card programs and products this October. This year’s record-breaking contribution represents an increase of more than 120% over the previous year and a cumulative donation of more than $6.4 million to BCRF. In 2010-11, Ann Taylor Stores Corporation is supporting four research projects: Dr. Kathy Miller from the Indiana University School of Medicine, Dr. Annette Stanton from UCLA, Dr. Carol Fabian from the University of Kansas, and Dr. Dawn Hershman from Columbia University. The 2010 donation will fund ten BCRF research projects in 2011-2012.Photo: Kara Ross, Myra Biblowit, Deborah Cavanagh, Robin Renzi and Gary Muto

Bloomingdale’s Pink CampaignOn September 29, many influential bloggers attended the kick-off for Bloomingdale’s Pink Campaign and The Estée Lauder Companies’ 2010 Breast Cancer Awareness Campaign at Bloomingdale’s flagship 59th Street store in NYC. Evelyn Lauder and Estée Lauder spokesmodel Elizabeth Hurley addressed an eager crowd, then signed specially designed Estée Lauder Pink Ribbon products benefiting BCRF.

Bloomingdale’s Pink Campaign included a variety of products from The Big Pink Umbrella (designed by BCRF Advisory Board member Marisa Acocella Marchetto) to The Little Pink Card, the “Give Pink, Get More” program, and the famous Little Pink Boutique. The 2010 Pink Campaign raised a phenomenal $1.3 million for BCRF, bringing the retailer’s total donation to over $3 million. Currently, Bloomingdale’s is supporting the research of Dr. Titia de Lange of The Rockefeller University in New York City and Dr. Joan Brugge of Harvard Medical School in Boston. Photos: Evelyn Lauder and Elizabeth Hurley pose with bloggers;Howard Kreitzman,Francine Klein and Elizabeth Hurley

The Estée Lauder Companies’ 2010 Breast Cancer Awareness CampaignEvery October, The Estée Lauder Companies un-folds its Breast Cancer Awareness (BCA) campaign. The company and employees sponsor a series of awareness and fundraising programs with the goal of informing millions of people each year about the importance of breast health and early detection and to raise funds for BCRF.

A cornerstone of the BCA campaign is the Estée Lauder Companies’ Global Landmark Illumination Initiative. In its 11th Anniversary, more than 200 famous buildings, monuments, and landmarks were illuminated in glowing pink lights to stand as international symbols of hope to empower and enlighten millions of women everywhere. The initiative launched with 38 global landmarks lit pink within 24 hours, achieving a new Guinness World Record, “Most Landmarks Illuminated for a Cause in 24 Hours.” Photos: The Estée Lauder Companies’ Sale-A-Bration volunteers; The Estée Lauder brand’s check presentation to Evelyn Lauder and BCRF; William Lauder and Rich Lehrer at Estée Lauder golf outing

PHO

TOS:

Wire

Imag

e.co

m


14

win

ter

2011

Cross Country for the Cure: Fairbury, ILThe Prairie Central Cross Country team held a “Cross Country for the Cure” run on October 26. The team started on Fairbury’s main street and ran around town until exhausted. Each member of the team ran for at least 80 minutes, and some ran for a full 120 minutes! The team members raised funds from the community, either as a flat donation or pledging a dollar amount per minute ran. The team raised over $2,600 and are excited to turn this into an annual event.

F Stop Breast Cancer: www.fstopbreastcancer.comLydia Shannon is a 23-year-old photographer. After finding out she has an 84% chance of getting breast cancer (based on genetic testing), she wanted to do something to make a difference. She told friends and family that if she raised $10,000, she would shave her head and donate her hair. She created an online photography auction and raffle called, F Stop Breast Cancer, which raised over $12,000; hence, her current baldness.

Camp Phoenix: Kabul, Afghanistan In a little over 40 days, Shamika Mitchell of Delta Detachment (82nd Financial Management Company in Fort Bragg, North Carolina), PFC Michelle Redner and SPC Erin Quinn of Bravo Company (186th BSB) planned a race in Camp Phoenix, Afghanistan. On October 23, 6:30 AM, more than 300 people came out to run four miles or walk two miles. They raised $3,000.

Bunco For Breast Cancer: Woodstock, ILOn October 17, the Crystal Lake Inn was buzzing with organizers and volunteers as they set-up for Woodstock’s 6th Annual Bunco For Breast Cancer event. The first of 600 guests arrived early and by 1pm, 50 huge baskets had been raffled, the room was filled to capacity and the Bunco started. It didn’t take long before $65,000 was raised! The Woodstock group – founded in 2005 by Susan Martino and her daughters, Tracy Noe and Laura Littner – has become the biggest and most successful group in the history of Bunco For Breast Cancer. Susan and her daughters are all breast cancer survivors and share an inspiring determination to support the Foundation’s mission. The event has cumulatively generated over $260,000 for BCRF. Photo: Laura Martino Littner, Tracy Martino Noe, Susan Martino, Walter Martino and Michelle Martino Mitchell

community fundraisers

Gail Hilson, ChairmanRoberta M. AmonJessie AraskogMuffie Potter AstonAnne H. BassCandice BergenMagda BleierMelinda BlinkenKatherine BryanSusan Payson BurkeCatherine CahillWendy CardunerPatty CisnerosNorma DanaBeth Rudin DeWoodyBarbaralee Diamonstein-SpielvogelRobin Chandler DukeHRH Princess FiryalAnne Eisenhower FlöttlMarjorie Reed Gordon

Lorna Hyde GraevJamee GregoryAudrey GrussJoanne de GuardiolaCandy HammMai Hallingby HarrisonDina Merrill HartleyGale HaymanVeronica HearstMarlene HessKaren M. KarpMariana KaufmanKitty KempnerEleanora KennedyCoco KopelmanJo Carole LauderKaren LauderKaren LeFrakWendy Vanderbilt LehmanMemrie M. Lewis

Nicole LimbockerCarol MackHillie MahoneyKetty MaisonrougeGrace T. MeigherLiz MezzacappaMuffy MillerNancy MissettGigi MortimerDeborah NorvilleLibby PatakiPat PattersonJean H. PearmanToni PeeblerCarroll PetriePauline PittPatricia QuickAnnette de la RentaPatricia RosenwaldHilary Geary Ross

June SchorrChristine Hearst SchwarzmanJeanne Sorensen SiegelNancy SilvermanAnne SitrickDaisy Soros Louise M. SunshineFelicia TaylorJoan H. TischAdrienne VittadiniBarbara WaltersPatricia G. WarnerThorunn WathneHarriet WeintraubSaundra WhitneyVivien Wyser-PrattePaula Zahn

BCRF Leaders Council

15

Thank You

Thanks to Jerry Kohl and his wife Terri, Brighton Collectibles is contributing 100% of the proceeds from a special pink ribbon charm to BCRF. Enclosed with the charm is a $20 check to BCRF. Customers mail the check to BCRF. This novel campaign has been widely successful and raised nearly $80,000 to date.

On September 13, Kmart and breast cancer survivor Jaclyn Smith (pictured with Mark Snyder, Chief Marketing Officer, Kmart) celebrated the 25th Anniversary of their design collabo-ration. $1 of any purchase from the limited-edition home and fashion collection was donated to BCRF.

Federico Lagrange of Northland (L) presented a $30,000 check to Jaclyn Lee of BCRF (R) at the BJ’s Wholesale Club in Miami. The donation was made possible through Northland’s Drink to Pink program, which BJ’s enthusiastically supported in their May 2010 promotion.

On October 25, Reed Krakoff hosted an evening at his new NYC store to celebrate BCRF, and honored the Foundation with a gift of $25,000. Pictured: Co-hosts Gigi Mortimer, Tory Burch, Reed Krakoff, Evelyn Lauder and Perri Peltz.

On July 12, Key Food organized a golf outing to raise $50,000 for BCRF. Pictured is Dean Janeway, Chief Executive Officer of Key Food Stores.

Nestle Waters doubled its donation and presented a $500,000 check to BCRF. Pictured: Robbie Franklin; Kim Jeffery, President and CEO, Nestle Waters North America; Myra Biblowit

Arlene AdlerRoberta M. AmonMelinda BlinkenMary BryantSusan Payson BurkeDarlene DaggettRena Rowan DamoneElisha DanielsUte Dugan, MD, PhDSuzanne ElsonAnne Eisenhower FlöttlStephanie GinsbergAmy P. Goldman, PhDBarbara GoldsmithRoslyn GoldsteinMarjorie Reed GordonLorna Hyde GraevBetsy S. GreenBette-Ann GwathmeyLori HallSusan HertogRonnie HeymanGail HilsonSusan B. HirschhornJane Hertzmark HudisRobin J. KemperRochelle KivellSandra KrakoffElyse LacherMaralyn LakinLaura LassmanEllen LevineMarisa Acocella Marchetto Ellen Odoner, Esq.Mary Alice PappasWinifred Gorlin PhillipsJane PontarelliPatricia Quick Katharine RaynerLynda ResnickWendi RosePatricia RosenwaldValerie SalembierSuzanne SantryJudith P. SchlagerMuriel SiebertAnne SitrickJoanne SmithErana StennettArlene TaubLinda WaintrupCathy WeinrothHarriet WeintraubCandace King WeirNina WexlerSara WolfensohnJacki Zehner Rhonda S. Zinner

BCRF Advisory Board


16

win

ter

2011

FEBRUARYThe Hot Pink Luncheon & Symposium Monday, February 7The Breakers, Palm Beach, FL

MARCHChallenge of the AmericasSaturday, March 12International Polo Club, Wellington, FL

Boston Hot Pink Party Kick-off Event Wednesday, March 16 David Yurman Copley Place, Boston

APRILThe Hot Pink Party with Sir Elton John Thursday, April 14The Waldorf=Astoria, NYC

MAYChappaqua’s A Cure in Our Lifetime Breakfast Friday, May 13Trump National Golf Club, Briarcliff Manor, NY

The Boston Hot Pink Party Tuesday, May 17Museum of Fine Arts, Boston

JULYBCRF Golf Classic Monday, July 18 Liberty National Golf Course, Jersey City, NJ

AUGUSTEstée Lauder’s “Play for Pink” Golf & Tennis ClassicMonday, August 15 Old Westbury Country Club, Old Westbury, NY

OCTOBERPink Promises Luncheon and SymposiumWednesday, October 12Long Island, NY

Symposium and Annual Awards LuncheonWednesday, October 26The Waldorf=Astoria, NYC

BCRF Board of Directors Evelyn H. Lauder, Founder and ChairmanMyra J. Biblowit, PresidentJeanette S. Wagner, Vice PresidentDeborah Krulewitch, Secretary and TreasurerCarolee FriedlanderKinga LampertCynthia LufkinCarlyn S. McCaffrey, Esq.Teruca RullánJosie Robertson, in memoriam

To Contact BCRF:646.497.2600 / 866 [email protected]

The Breast Cancer Research Foundation60 East 56th Street, 8th FloorNew York, New York 10022

ADDRESS SERVICE REQUESTED

NON-PROFIT

US POSTAGE PAID

NEW YORK, NY

PERMIT NO. 2377

2011 PINK Calendar

PRIN

TED

ON

REC

YC

LED

PA

PER

Executive Board of Scientific Advisors

Chairman and Scientific DirectorLarry Norton, MDMemorial Sloan-Kettering Cancer Center

MembersNancy E. Davidson, MDUniversity of Pittsburgh Cancer Institute

Peter Greenwald, MD, Dr.PHNational Cancer InstituteNational Institutes of Health

Gabriel N. Hortobagyi, MDUniversity of TexasMD Anderson Cancer Center

Scientific Advisory Committee

ChairmanClifford Hudis, MD Memorial Sloan-Kettering Cancer Center

MembersPatricia A. Ganz, MDJonsson Comprehensive Cancer CenterUniversity of California, Los Angeles

Judy E. Garber, MD, MPHDana-Farber Cancer Institute Harvard Medical School

Lajos Pusztai, MD, D.PhilUniversity of TexasMD Anderson Cancer Center

Vered Stearns, MDJohns Hopkins University School of Medicine

PHO

TOS:

Rob

Ric

h

The breast Cancer Research FoundationPink Press · The breast Cancer Research Foundation® 2 winter...

Documents

Transcript of The breast Cancer Research FoundationPink Press · The breast Cancer Research Foundation® 2 winter...